Landscape Capital Management L.L.C. Raises Position in Progyny, Inc. (NASDAQ:PGNY)

Landscape Capital Management L.L.C. boosted its position in Progyny, Inc. (NASDAQ:PGNY) by 126.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 167,157 shares of the company’s stock after purchasing an additional 93,374 shares during the period. Landscape Capital Management L.L.C.’s holdings in Progyny were worth $2,802,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of PGNY. Janney Montgomery Scott LLC purchased a new position in shares of Progyny during the 1st quarter valued at $213,000. Vanguard Group Inc. lifted its holdings in Progyny by 0.5% during the first quarter. Vanguard Group Inc. now owns 8,311,840 shares of the company’s stock valued at $317,097,000 after purchasing an additional 41,687 shares during the last quarter. EntryPoint Capital LLC lifted its holdings in Progyny by 90.2% during the first quarter. EntryPoint Capital LLC now owns 3,989 shares of the company’s stock valued at $152,000 after purchasing an additional 1,892 shares during the last quarter. PEAK6 Investments LLC boosted its position in Progyny by 68.1% during the first quarter. PEAK6 Investments LLC now owns 10,942 shares of the company’s stock worth $417,000 after purchasing an additional 4,433 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of Progyny by 5.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 54,912 shares of the company’s stock worth $2,095,000 after purchasing an additional 2,947 shares in the last quarter. 94.93% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 target price on shares of Progyny in a report on Tuesday, October 1st. BTIG Research downgraded shares of Progyny from a “buy” rating to a “neutral” rating in a report on Wednesday, August 7th. Leerink Partnrs lowered shares of Progyny from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 7th. Jefferies Financial Group lowered their target price on shares of Progyny from $31.00 to $24.00 and set a “buy” rating on the stock in a research note on Thursday, September 19th. Finally, Canaccord Genuity Group downgraded shares of Progyny from a “buy” rating to a “hold” rating and cut their price target for the company from $37.00 to $24.00 in a report on Wednesday, August 7th. Eight analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $25.42.

Progyny Trading Up 2.3 %

Shares of NASDAQ PGNY opened at $13.98 on Thursday. The stock’s 50-day moving average is $16.74 and its 200 day moving average is $22.92. The stock has a market cap of $1.19 billion, a price-to-earnings ratio of 24.10, a P/E/G ratio of 1.65 and a beta of 1.44. Progyny, Inc. has a 1-year low of $13.39 and a 1-year high of $42.08.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.26). Progyny had a return on equity of 11.36% and a net margin of 5.03%. The business had revenue of $286.63 million during the quarter, compared to the consensus estimate of $296.85 million. During the same period in the prior year, the firm earned $0.16 earnings per share. The business’s revenue for the quarter was up 2.0% on a year-over-year basis. On average, analysts forecast that Progyny, Inc. will post 0.56 EPS for the current fiscal year.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.